Multiple reports say a heart medication designed to reduce inflammation does not achieve the expected benefits in a clinical setting, leading researchers to reassess a long-held view about the cause of heart disease. The drug’s approach centers on lowering inflammatory activity, based on the theory that inflammation plays a key role in developing and progressing cardiovascular conditions. However, the trial results do not support that premise, according to the accounts. Experts cited in the coverage describe the outcome as a significant setback for the inflammation-focused model of heart disease, noting that the failure may indicate the relationship is more complex than previously assumed, or that targeting inflammation with this specific therapy is not sufficient to improve clinical outcomes. While the results challenge prevailing assumptions, the reports frame the findings as prompting further investigation rather than settling the debate. Researchers are now looking for explanations that could include differences between the targeted inflammatory pathways and the biological mechanisms that drive heart disease.